RCMNY
ARQT icon

Rubric Capital Management (New York)’s Arcutis Biotherapeutics ARQT Stock Holding History

Rubric Capital Management (New York)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$195M Hold
8,271,577
– – 2.06% 11
2025
Q4 		$240M Sell
8,271,577
-2,477,880
-23% -$63.4M 2.87% 7
2025
Q3 		$203M Hold
10,749,457
– – 2.29% 9
2025
Q2 		$151M Sell
10,749,457
-217,215
-2% -$3.05M 2.28% 11
2025
Q1 		$172M Hold
10,966,672
– – 3.07% 8
2024
Q4 		$153M Hold
10,966,672
– – 1.96% 11
2024
Q3 		$102M Buy
10,966,672
+1,150,000
+12% +$11.3M 1.66% 11
2024
Q2 		$91.3M Buy
9,816,672
+2,306,672
+31% +$20.9M 2.39% 12
2024
Q1 		$74.4M Buy
7,510,000
+865,470
+13% +$6.46M 2.2% 13
2023
Q4 		$21.5M Buy
6,644,530
+1,610,000
+32% +$4.38M 0.45% 37
2023
Q3 		$26.7M Buy
5,034,530
+150,000
+3% +$1.28M 1% 31
2023
Q2 		$46.5M Buy
4,884,530
+1,384,530
+40% +$15.4M 1.99% 21
2023
Q1 		$38.5M Buy
3,500,000
+757,481
+28% +$11M 1% 28
2022
Q4 		$40.6M Buy
2,742,519
+2,270,472
+481% +$39.7M 1.77% 21
2022
Q3 		$9.02M Buy
472,047
+245,701
+109% +$5.57M 0.45% 47
2022
Q2 		$4.82M Buy
+226,346
New +$4.64M 0.25% 62

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rubric Capital Management (New York)'s ARQT Position: Q1 2026 in Review

Rubric Capital Management (New York) held its Arcutis Biotherapeutics (ARQT) position steady in Q1 2026 at 8,271,577 shares worth $195M. The position accounts for 2.06% of the portfolio, ranked #11.

Rubric Capital Management (New York) first reported a position in ARQT in Q2 2022 and has held it in 16 quarters since. The position peaked at $240M in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Rubric Capital Management (New York) held 8,271,577 shares of Arcutis Biotherapeutics worth $195M as of Q1 2026.
  • Rubric Capital Management (New York) left its Arcutis Biotherapeutics share count unchanged in Q1 2026.
  • Arcutis Biotherapeutics made up 2.06% of Rubric Capital Management (New York)'s portfolio in Q1 2026, its #11 holding.
  • Rubric Capital Management (New York) first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 16 quarters since.
  • Rubric Capital Management (New York)'s Arcutis Biotherapeutics position peaked at $240M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2026, filed 15 May 2026.